2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155749
    AChE-IN-36 2978753-66-9 98%
    AChE-IN-36 (compound A4) is anacetylcholinesterase inhibitorswith an IC50 of 0.04 μM. AChE-IN-36 effects ROS levels and gene expression of NRF2.
    AChE-IN-36
  • HY-155750
    AChE-IN-37 2978753-64-7 99.77%
    AChE-IN-37 (compound A2) is anacetylcholinesterase inhibitorswith an IC50 of 0.23 μM. AChE-IN-37 effects ROS levels and gene expression of NRF2.
    AChE-IN-37
  • HY-155762
    Anti-neuroinflammation agent 1 2968412-77-1 98%
    Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype.
    Anti-neuroinflammation agent 1
  • HY-155801
    CRX 527 216014-14-1 98%
    CRX 527 is a TLR4 agonist. CRX 527 activates the MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, and regulates antigen processing and presentation by dendritic cells. CRX 527 stimulates innate immune responses and enhances vaccine efficacy. CRX 527 maintains the structural integrity of hematopoietic tissues, spleen and intestine, alleviates radiation-induced damage, preserves intestinal homeostasis, and inhibits apoptosis, inflammatory responses, oxidative stress and DNA damage. CRX 527 can be used in the research of acute radiation syndrome, melanoma, HPV-related tumors and intracerebral hemorrhage.
    CRX 527
  • HY-155822
    TZ3O 98.17%
    TZ3O is an anticholinergic agent with neuroprotective effects. TZ3O inhibits acetylcholinesterase (AChE) activity in human plasma with an IC50 of 304.5 μM. TZ3O can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research.
    TZ3O
  • HY-155823
    TZ4M 98%
    TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model.
    TZ4M
  • HY-155949
    Bt354 931305-29-2 98%
    Bt354 is an orally active STAT3 inhibitor with IC50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain.
    Bt354
  • HY-155958
    Casein kinase 1δ-IN-9 854355-54-7 98.0%
    Casein kinase 1δ-IN-9 (compound 737) is a potent casein kinase 1δ (CK1δ/CK15) inhibitor. Casein kinase 1δ-IN-9 can be used for the research of neurodegenerative disorders such as Alzheimer's disease.
    Casein kinase 1δ-IN-9
  • HY-155989
    GSK3-IN-4 748145-19-9 98%
    GSK3-IN-4 (compound 0715) is a potent GSK3 inhibitor. GSK3-IN-4 can be used for psychiatric disorder research.
    GSK3-IN-4
  • HY-156011
    PSEN1-IN-1 98%
    PSEN1-IN-1 (Compound (+)-13b) is a PSEN1 inhibitor. PSEN1-IN-1 inhibits PSEN1-APH1A and PSEN1-APH1B complex with IC50s of 19 and 5.5 nM. PSEN1-IN-1 can be used for Alzheimer's disease research.
    PSEN1-IN-1
  • HY-156017
    5-HT6R antagonist 1 98%
    5-HT6R antagonist 1 (Comopund 8) is a 5-HT6R antagonist (Ki: 5 nM). 5-HT6R antagonist 1 inhibits platelet aggregation. 5-HT6R antagonist 1 has excellent metabolic stability. 5-HT6R antagonist 1 reverses MK-801 (HY-15084B)-induced memory impairments in rats. 5-HT6R antagonist 1 can be used for Alzheimer's disease (AD) research.
    5-HT6R antagonist 1
  • HY-156030
    AChE-IN-40 98%
    AChE-IN-40 (Compound 5C) is an AChE inhibitor (IC50: 120 nM). AChE-IN-40 can be used for research of Alzheimer's disease.
    AChE-IN-40
  • HY-156031
    BChE-IN-19 98%
    BChE-IN-19 (Compound 7b) is a para-substituted derivative of indone (7b) with inhibitory activity of butyryl cholinesterase (BChE) (IC50=0.04 μM). BChE-IN-19 improves cholinergic scheduling in the nervous system. BChE-IN-19 can be used against Alzheimer's disease.
    BChE-IN-19
  • HY-156032
    PIMPC 2250244-44-9 98%
    PIMPC is a compound with antioxidant and metal-chelating properties. PIMPC is a novel inhibitor of glycogen synthase kinase 3 (GSK-3). PIMPC has potential anti-Alzheimer's disease effect.
    PIMPC
  • HY-156054
    N-Hydroxy riluzole 179070-90-7 98%
    N-Hydroxy riluzole is a metabolite of the antiglutamatergic agent Riluzole (HY-B0211).
    N-Hydroxy riluzole
  • HY-156059
    NEP28 1254176-87-8
    NEP28 is a selective androgen receptor modulator with an EC50 of 2.90 nM in 22RV1 cells. NEP28 increases the activity of Aβ-degrading enzyme neprilysin. NEP28 is efficacious in muscle and brain without serious side effects on prostate in rats. NEP28 can be used for osteoporosis, sarcopenia, and Alzheimer's disease research.
    NEP28
  • HY-156061
    NAP-1 131721-28-3 98%
    NAP-1 is a compound with agent that can suppress or relieve pain. effects. NAP-1 enhances the inhibitory current by binding to a specific site of GABAaR, resulting in a narcotic effect. NAP-1 can be used in research to develop clinical agent that can suppress or relieve pain.
    NAP-1
  • HY-156079
    Antidepressant agent 5 1071049-42-7 98%
    Antidepressant agent 5 (Compound 3i) is a 7-substituted tetrahydroisoquinolines derivatives. Antidepressant agent 5 exhibits almost equal antidepressant activity compared with magnoflorine. ntidepressant agent 5 can be used for depressive disorder research.
    Antidepressant agent 5
  • HY-15608R
    MPTP hydrochloride (Standard) 23007-85-4 98%
    Iproniazid (phosphate) (Standard) is the analytical standard of Iproniazid (phosphate). This product is intended for research and analytical applications. Iproniazid phosphate is a non-selective, irreversible monoamine oxidase (MAO) inhibitor of the hydrazine class. Iproniazid phosphate has antidepressive activity.
    MPTP hydrochloride (Standard)
  • HY-156102
    c-ABL-IN-5 3056613-20-5 98%
    c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD).
    c-ABL-IN-5
Cat. No. Product Name / Synonyms Application Reactivity